Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Venetoclax plus LDAC tops LDAC alone in AML

Key clinical point: Low dose cytarabine (LDAC) plus venetoclax improved survival, rates of remission, and event free survival in acute myelogenous leukemia (AML) patients ineligible for intensive chemotherapy, compared with LDAC alone.

Major finding: At about 18 months follow-up median overall survival was 8.4 months versus 4.1 months with LDAC plus venetoclax versus LDAC plus placebo.

Study details: Randomized, double-blind phase 3 trial.

Disclosures: The trial was funded by venetoclax maker AbbVie, which was involved with data interpretation and other matters. The lead investigator is a consultant for and receives research funding from the company and also receives royalty payments in relation to venetoclax.


Wei AH et al. EHA CONGRESS, Abstract S136.